Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Creaven

Showing results (1-10 of 130) with videos related to

Pageof 13
Sort By:
The Prostate|January 1, 1984
Rationale for chemotherapeutic approaches to prostate cancerP J Creaven
Urology|March 1, 1984
Platinum analogs as potential new drugs for bladder cancerP J Creaven
The Prostate|January 1, 1984
Cytotoxic chemotherapeutic agents under development with a possible future role in prostate cancerP J Creaven
Cancer Chemotherapy and Pharmacology|January 1, 1982
The clinical pharmacology of VM26 and VP16-213. A brief overviewP J Creaven
Advances in Experimental Medicine and Biology|January 1, 1988
5-Fluorouracil and folinic acid: summary of clinical experienceP J Creaven
Bulletin Du Cancer|January 1, 1979
Pharmacokinetic parameters: potential for and problems with their use as predictors of response to cancer chemotherapeutic agentsP J Creaven
Journal of the Irish Dental Association|March 1, 1974
Dental materials--a short guide for the general practitioner. 2. Linings and cementsP J Creaven
Cancer Research|December 15, 1993
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatinL Pendyala, P J Creaven
Seminars in Oncology|June 1, 1977
The clinical toxicity of anticancer drugs and its predictionP J Creaven, E Mihich
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 1, 1995
Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trialL Pendyala, P J Creaven
Pageof 13

Showing results (1-10 of 130) with videos related to

Sort By:
Pageof 13
The Prostate|January 1, 1984
Rationale for chemotherapeutic approaches to prostate cancerP J Creaven
Urology|March 1, 1984
Platinum analogs as potential new drugs for bladder cancerP J Creaven
The Prostate|January 1, 1984
Cytotoxic chemotherapeutic agents under development with a possible future role in prostate cancerP J Creaven
Cancer Chemotherapy and Pharmacology|January 1, 1982
The clinical pharmacology of VM26 and VP16-213. A brief overviewP J Creaven
Advances in Experimental Medicine and Biology|January 1, 1988
5-Fluorouracil and folinic acid: summary of clinical experienceP J Creaven
Bulletin Du Cancer|January 1, 1979
Pharmacokinetic parameters: potential for and problems with their use as predictors of response to cancer chemotherapeutic agentsP J Creaven
Journal of the Irish Dental Association|March 1, 1974
Dental materials--a short guide for the general practitioner. 2. Linings and cementsP J Creaven
Cancer Research|December 15, 1993
In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatinL Pendyala, P J Creaven
Seminars in Oncology|June 1, 1977
The clinical toxicity of anticancer drugs and its predictionP J Creaven, E Mihich
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 1, 1995
Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trialL Pendyala, P J Creaven
Pageof 13